Assessment of treatment options for patients with hepatitis C virus recombinant form 2k/1b.

Mamuka ZakalashviliJaba ZarkuaRobert G GishMaia ZhamutashviliVakhtang SartaniaMichael WeizeneggerJan BartelMonika RaabeLia GvinjiliaSophia MetreveliMaka BarnovaNikoloz AbramishviliIrakli RtskhiladzeDavid Metreveli

Published in: Hepatology research : the official journal of the Japan Society of Hepatology (2020)

Sofosbuvir-based regimens are highly effective for treatment of RF 2k/1b patients, and with availability of new pan-genotypic direct-acting antivirals, genotyping to identify RF 2k/1b patients might not be necessary.

Keyphrases

hepatitis c virus
end stage renal disease
ejection fraction
newly diagnosed
peritoneal dialysis
prognostic factors
gene expression
genome wide